Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis
  Free Subscription

Articles published in
Vaccine
    October 2026
  1. NIEMINEN T, Nurhonen M, Leino T, Salo H, et al
    Cost-effectiveness of universal infant hepatitis B vaccination programme in Finland.
    Vaccine. 2026;94:129171.
    >> Share

    September 2026
  2. SEMPERE L, Almenta I, Barrenengoa J, Gutierrez A, et al
    Corrigendum to 'Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease' [Vaccine 31 (2013) 3065-3071].
    Vaccine. 2026 Sep 28:129140. doi: 10.1016/j.vaccine.2026.129140.
    >> Share

  3. MONTES CAMINO LM, Aldea M, Martinez C, Garcia-Basteiro AL, et al
    Evaluation of the immunogenicity of hepatitis B vaccination in hematopoietic stem cell transplant recipients vaccinated with a hexavalent vaccine compared with patients vaccinated with a combined hepatitis A and B vaccine.
    Vaccine. 2026;93:129183.
    >> Share

    August 2026
  4. LI F, Wang J, Zhang W
    Hepatitis B among hospital nurses worldwide: a meta-analysis of seroprevalence studies.
    Vaccine. 2026;90:128972.
    >> Share

    July 2026
  5. REAGAN EK, Wright DA, Clark KE, Mercado-Lopez X, et al
    mRNA-LNP hepatitis C vaccine encoding p7 elicits improved humoral immunogenicity.
    Vaccine. 2026;88:128938.
    >> Share

    June 2026
  6. GANDHI V, Kinariwala K, Kesling GL
    Under-vaccination as a systems failure: A Monte Carlo simulation of the 2025 CDC/ACIP hepatitis B birth-dose policy shift and multi-level intervention packages, 2025-2035.
    Vaccine. 2026;89:128883.
    >> Share

  7. CORPUZ GS, Sidhu AS, Konig DJ, Waljee JF, et al
    On the implications of shifting Hepatitis B vaccine policy for surgical patients.
    Vaccine. 2026;88:128791.
    >> Share

    May 2026
  8. DIVANI M, Katsanaki A, Poulianiti C, Lykotsetas E, et al
    Lipid peroxidation marker malondialdehyde is an independent determinant of hepatitis B vaccine response in hemodialysis patients.
    Vaccine. 2026;87:128776.
    >> Share

  9. CASSIMOS DC, Effraimidou E, Irakleidou I, Medic S, et al
    Vaccine-preventable disease outbreaks in schools, part 2: pertussis, meningococcal disease, diphtheria, poliomyelitis, hepatitis A, and rotavirus infection.
    Vaccine. 2026;86:128750.
    >> Share

    April 2026
  10. WANG X, Wu T
    Advancements in therapeutic HBV vaccines: navigating the path toward functional cure.
    Vaccine. 2026;82:128610.
    >> Share

  11. VANDE HEY JM, Ward D, Buys A, Caldera F, et al
    Hepatitis B challenge dose in vaccinated healthcare personnel susceptible at hire.
    Vaccine. 2026;82:128589.
    >> Share

  12. AGRAWAL N, Mercedes R, Moulton EA, Sahni LC, et al
    Adherence to hepatitis B birth dose vaccine recommendations in two hospital systems in Houston.
    Vaccine. 2026;80:128564.
    >> Share

    March 2026
  13. ALKAN C, Jurado-Cobena E, Ikegami T
    Evaluation of Rift Valley fever vaccine candidates in pregnant rodent models.
    Vaccine. 2026;80:128526.
    >> Share

  14. HUANG A, Li J, Tang L, Xu X, et al
    Cost-effectiveness of hepatitis A vaccination for adults in China: A decision tree Markov model study.
    Vaccine. 2026;79:128509.
    >> Share

  15. TROCCOLI CS, Nascimento PS, Villar LM, Miguel JC, et al
    Long-term persistence of Seroprotection following a modified hepatitis B vaccine schedule in people living with HIV.
    Vaccine. 2026;79:128483.
    >> Share

    February 2026
  16. LOEHR J, Moser CA, Asturias EJ, Shaw AC, et al
    Science for vaccine policy: Lack of transparency, misinformation, and poor decision processes at the December 2025 ACIP meeting.
    Vaccine. 2026;76:128338.
    >> Share

    January 2026
  17. LI J, Kyaw PE, Tan C, Wen K, et al
    Development of duck hepatitis A virus type 1 attenuated vaccine E23-SP80 and its protective efficacy evaluation against DHAV-1 infection in ducks.
    Vaccine. 2026;75:128258.
    >> Share

  18. SHENG S, Sun Y, Qin J, Zhao J, et al
    Hepatitis B core antigen-based trivalent VLP vaccine against porcine viral diarrhea.
    Vaccine. 2026;74:128210.
    >> Share

  19. GRACE A, Schick V, Quan FT, Troisi C, et al
    Hepatitis B vaccination series completion among residents of low-income housing in Texas: An exploratory analysis of demographic and clinical factors.
    Vaccine. 2026;70:128037.
    >> Share

    December 2025
  20. FEBRIANI Y, Ursu MM, Sauvageau C, Kegbevi KB, et al
    Immune memory assessment three years following a single dose of hepatitis a vaccine at 12, 13 or 19 months of age.
    Vaccine. 2025;73:128144.
    >> Share

    November 2025
  21. VAHABI MM, Ketentzi S, Kahraman U, Erdem HA, et al
    A single center's 25-year experience with hepatitis B and pneumoccocal vaccines in heart transplant patients: the impact of the COVID-19 pandemic.
    Vaccine. 2025;70:128023.
    >> Share

    October 2025
  22. LIU X, Han S, Wang H, Sun L, et al
    Immunogenicity and safety of co-administration of sabin-strain-based inactivated poliovirus vaccine, diphtheria-tetanus-acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled
    Vaccine. 2025;67:127891.
    >> Share

  23. COLLINS C, Ratshisusu L, Modise LM, Simani OE, et al
    Hepatitis B virus infection and vaccine coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.
    Vaccine. 2025;66:127843.
    >> Share

  24. RACCAGNI AR, Morsica G, Reali P, Lolatto R, et al
    Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.
    Vaccine. 2025;66:127825.
    >> Share

    September 2025
  25. KANG W, Wang F, Hao Z, Zhang Z, et al
    A follow-up study on the protective efficacy and anamnestic response of recombinant CHO hepatitis B vaccine 26 years after immunization.
    Vaccine. 2025;64:127743.
    >> Share

    August 2025
  26. BARLOW M, Flanagan S, Ghosh I, Carter J, et al
    Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?
    Vaccine. 2025;63:127639.
    >> Share

  27. GAO L, Zhang X, Mo X, Sun Y, et al
    Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China.
    Vaccine. 2025;62:127596.
    >> Share

    July 2025
  28. GAO S, Cai M, Su M, Zhao T, et al
    Influencing factors and trends in post-vaccination serologic testing completion rates among infants born to HBsAg-positive mothers in Guangdong Province, 2021-2023.
    Vaccine. 2025;62:127565.
    >> Share

  29. LI J, Wang X, Zhang D, Xie F, et al
    Safety and immunogenicity of thiomersal-free recombinant hepatitis E vaccine: A randomized, double-blind, active-controlled study.
    Vaccine. 2025;62:127510.
    >> Share

    June 2025
  30. SONG Y, Feng Y, Jiang F, Xu X, et al
    The HBV seroprevalence and immune responses to hepatitis B vaccination among college students from four universities in China.
    Vaccine. 2025;61:127408.
    >> Share

    May 2025
  31. GANDHI K, Vijay Y, Page K, Dahari H, et al
    Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
    Vaccine. 2025;59:127256.
    >> Share

  32. HUNG SH, Torres JL, Chen F, Giang E, et al
    Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.
    Vaccine. 2025;58:127239.
    >> Share

    April 2025
  33. WIBOWO DP, Chalid MT, Rasyak MR, El Khobar KE, et al
    Characteristics of hepatitis B virus surface protein and occult hepatitis B infection in infants with immunoprophylaxis failure from Indonesia.
    Vaccine. 2025;56:127130.
    >> Share

  34. WANG F, Zheng J, Qiu F, Yang Y, et al
    Long-term effectiveness of vaccination for prevention of hepatitis B virus mother-to-child transmission in Yunnan, China.
    Vaccine. 2025;54:127128.
    >> Share

    March 2025
  35. OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
    Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
    Vaccine. 2025;55:127051.
    >> Share

  36. VYSOTSKAYA V, Gassowski M, Kasper A, Gasich E, et al
    Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus.
    Vaccine. 2025;55:127058.
    >> Share

  37. KANG M, Marks KM, Cox AL, Sherman KE, et al
    An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
    Vaccine. 2025;55:127028.
    >> Share

  38. GHARPURE R, Vegvari C, Abdissa A, Alimi Y, et al
    Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.
    Vaccine. 2025;54:126860.
    >> Share

    January 2025
  39. JIANG Y, Luo Y, Xiao X, Li X, et al
    Global, regional, and national burdens of vaccine-preventable infectious diseases with high incidence among middle-aged and older adults aged 55-89 years from 1990 to 2021: Results from the global burden of disease study 2021.
    Vaccine. 2025;49:126786.
    >> Share

  40. KHETSURIANI N, Tursunova D, Kasimova R, Sharapov S, et al
    Prevalence of chronic hepatitis B virus infection among children in Uzbekistan: Impact of vaccination.
    Vaccine. 2025;48:126743.
    >> Share

  41. CHIU CY, Sampathkumar P, Brumble LM, Vikram HR, et al
    Optimizing hepatitis B virus seroprotection in thoracic organ transplantation: The role of HepB-CpG (Heplisav-B) vaccination schedule.
    Vaccine. 2025;47:126705.
    >> Share

  42. SEO H, Kim BJ, Oh J, Jung S, et al
    Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.
    Vaccine. 2025;47:126710.
    >> Share

  43. SU Q, Qiu F, Gao Z, Zhao Y, et al
    Long-term efficacy and anamnestic response of hepatitis B vaccine derived from Chinese hamster ovary cell after 18-20 years.
    Vaccine. 2025;47:126655.
    >> Share

    November 2024
  44. GRIGAS J, Spancerniene U, Simanavicius M, Pautienius A, et al
    Adaptive immune response to a wild boar-derived recombinant hepatitis e virus capsid protein challenge in pigs.
    Vaccine. 2024 Nov 30:126561. doi: 10.1016/j.vaccine.2024.126561.
    >> Share

  45. BERTHOUD TK, Ahmed T, Nadia W, Petrov I, et al
    A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.
    Vaccine. 2024;43.
    >> Share

    October 2024
  46. NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
    Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
    Vaccine. 2024;42:126462.
    >> Share

  47. AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al
    A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
    Vaccine. 2024;42:126461.
    >> Share

  48. KANG S, Chung E, Hong C, Aziz AB, et al
    Raising the case of hepatitis E: Report from the 2nd international HEV symposium.
    Vaccine. 2024;42:126398.
    >> Share

    September 2024
  49. HOU X, Li N, Zhang H, Liu W, et al
    Hepatitis B virus infection and vaccination among people who use drugs in Xi'an, China.
    Vaccine. 2024;42:126259.
    >> Share

    August 2024
  50. DONG R, Luo Z, Shao J, Xue H, et al
    Understanding hepatitis E vaccination intention among women of childbearing-age: A theory-based cross-sectional study.
    Vaccine. 2024;42:126258.
    >> Share

  51. KANU FA, Freeland C, Nwokoro UU, Mohammed Y, et al
    Evaluation of interventions to improve timely hepatitis B birth dose vaccination among infants and maternal tetanus vaccination among pregnant women in Nigeria.
    Vaccine. 2024;42:126222.
    >> Share

    July 2024
  52. BESBASSI H, Elias G, Meysman P, Jansens H, et al
    Modeling antigen-specific T cell dynamics following Hepatitis B Vaccination indicates differences between conventional and regulatory T cell dynamics.
    Vaccine. 2024;42:126148.
    >> Share

  53. MESHRAM R, Kolte B, Gacche R
    Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept.
    Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  54. KOUTSOUMPLI G, Stasiukonyte N, Hoogeboom BN, Daemen T, et al
    An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
    Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024.
    >> Share

    February 2024
  55. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    >> Share

    January 2024
  56. SANTORO PE, Paladini A, Borrelli I, Amantea C, et al
    Vaccine-preventable diseases: Immune response in a large population of healthcare students.
    Vaccine. 2024 Jan 20:S0264-410X(24)00049-5. doi: 10.1016/j.vaccine.2024.
    >> Share

    December 2023
  57. DIONNE M, Sauvageau C, Kiely M, Dahhou M, et al
    School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec.
    Vaccine. 2023 Dec 2:S0264-410X(23)01419-6. doi: 10.1016/j.vaccine.2023.
    >> Share

    September 2023
  58. SANADA T, Oda Y, Ohashi C, Isotani K, et al
    Hybrid large hepatitis B surface protein composed of two viral genotypes C and D induces strongly cross-neutralizing antibodies.
    Vaccine. 2023 Sep 20:S0264-410X(23)01096-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  59. BIRNBAUM JA, Guttman D, Parulekar M, Omarufilo F, et al
    Eliminating hepatitis B vaccination disparities for West African immigrants.
    Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  60. SUSARLA SK, Gupta M, Uttam KG, Palkar S, et al
    Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
    Vaccine. 2023 Sep 1:S0264-410X(23)01050-2. doi: 10.1016/j.vaccine.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016